Skip to main content
. 2020 Aug 4;12(8):731. doi: 10.3390/pharmaceutics12080731

Table 1.

Factors and levels of the L9 (34) orthogonal design for SLNs (solid lipid nanoparticles).

Variable Level
1 2 3
Type (A) PVA (Polyvinyl alcohol) PVP (Poly-vinyl pyrrolidone) Poloxamer188
Concentration (B) 1% 2% 3%
Volume (C) 15 mL 20 mL 25 mL

(A) emulsifier type; (B) aqueous phase concentration; (C) aqueous phase volume.